Cipher Pharmaceuticals (TSE:CPH) Stock Breaks Above 50-Day Moving Average – What’s Next?

Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR)’s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$13.76 and traded as high as C$15.00. Cipher Pharmaceuticals shares last traded at C$14.17, with a volume of 89,992 shares changing hands.

Cipher Pharmaceuticals Trading Up 4.1%

The business has a 50-day moving average price of C$13.76 and a two-hundred day moving average price of C$15.73. The stock has a market capitalization of C$360.13 million, a P/E ratio of 12.65 and a beta of 1.29. The company has a current ratio of 1.59, a quick ratio of 2.67 and a debt-to-equity ratio of 0.27.

Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last issued its quarterly earnings results on Thursday, November 12th. The company reported C$0.60 EPS for the quarter. The company had revenue of C$18.08 million for the quarter. Cipher Pharmaceuticals had a return on equity of 22.74% and a net margin of 58.81%. On average, analysts expect that Cipher Pharmaceuticals Inc. will post 1.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Craig Mull acquired 20,000 shares of Cipher Pharmaceuticals stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the completion of the purchase, the director directly owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their position. 42.00% of the stock is owned by corporate insiders.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.

Read More

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.